Disease · MONDO_0016383

nephrogenic diabetes insipidus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nephrogenic diabetes insipidus. Diseases, record MONDO_0016383. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016383

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nephrogenic diabetes insipidus; Open Targets
Open Targets ID: MONDO_0016383; Open Targets
Disease Ontology: DOID:12387; Disease Ontology
MeSH: D018500; MeSH
NCI Thesaurus: C84919; NCI Thesaurus
Orphanet: ORPHA:223; Orphanet
Highest stage of its drugs: Phase 2, for 1 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CALCITONIN	CHEMBL4594242	Protein	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
SILDENAFIL	CHEMBL192	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets54

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CALCR	Calcitonin receptor	1	Calcitonin receptor agonist	Unknown	https://conductscience.org/library/genes/799	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1	https://conductscience.org/library/genes/56901	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 1	https://conductscience.org/library/genes/2820	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Phase 2	https://conductscience.org/library/genes/3156	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1	https://conductscience.org/library/genes/4537	Drugs and targets
MT-ND4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1	https://conductscience.org/library/genes/4538	Drugs and targets
MT-ND4L	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1	https://conductscience.org/library/genes/4539	Drugs and targets

1 to 10 of 54

See all 54 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00478335	Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus	Not applicable	4	2018-02-12	Nephrogenic Diabetes Insipidus	CALCITONIN, SILDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT02967653	Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus	Phase 2	60		Lithium Use, Nephrogenic Diabetes Insipidus	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02460354	Metformin and Congenital Nephrogenic Diabetes Insipidus	Phase 1	2		Diabetes Insipidus	METFORMIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Experimental First Then Standard vs Standard First Then Experimental: serious adverse events	0 of 2	0 of 2	4	NCT00478335

Source Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32621644	DERIVED	1	PubMed
30012135	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016383

GET https://conductscience.org/api/diseases/v1/MONDO_0016383/targets?page=2

API reference For AI assistants